Brief: Silk Road Medical Says Transcarotid Artery Revascularization Continues To Show Low Stroke And Death Rate
22/11/2019 19:57
Nov 22 (Reuters) - Silk Road Medical Inc SILK.O :
* SILK ROAD MEDICAL - TRANSCAROTID ARTERY REVASCULARIZATION
(TCAR)
CONTINUES TO SHOW A LOW STROKE AND DEATH RATE EQUIVALENT TO
CAROTID ENDARTERECTOMY
* SILK ROAD MEDICAL INC - "TCAR PATIENTS EXPERIENCE SHORTER
LENGTH
OF HOSPITAL STAY AND ARE DISCHARGED HOME MORE OFTEN"
Source text for Eikon: ID:nGNX6XqfsZ
Further company coverage: SILK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silk Road Medical
See all newsBrief: Silk Road Medical Boston Scientific To Be Required To Pay Co Termination Fee Of $69.5 Million If Merger Agreement Terminated Under Certain Circumstances
Boston Scientific to buy Silk Road Medical in $1.16 billion deal (updated)
Brief: Boston Scientific Announces Agreement to Acquire Silk Road Medical
Brief: Silk Road Medical Announces Definitive Agreement To Be Acquired By Boston Scientific
Boston Scientific to buy Silk Road Medical for $1.16 billion